Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1993 Aug;79(4):673–680.

Anti-idiotypic immunization provides protection against lethal endotoxaemia in BALB/c mice.

J J Cornelissen 1, K Maassen 1, L van Emst 1, P M Weers 1, M Harmsen 1, B J Benaissa-Trouw 1, T A Oosterlaken 1, C A Kraaijeveld 1, J Verhoef 1
PMCID: PMC1421928  PMID: 8406595

Abstract

Against lipid A (the conserved moiety of lipopolysaccharides from Gram-negative bacteria) neutralizing IgM monoclonal antibodies (mAb) 8-2 and 26-20 anti-idiotypic (Ab2) mAb were produced: Ab2 mAb KM-04 (IgG1) against mAb 8-2, and Ab2 mAb PW-1 (IgG2a) and PW-2 (IgG1) against mAb 26-20. The binding of Ab2 mAb KM-04 to 8-2 (Ab1) was strongly inhibited by a lipopolysaccharide (LPS) extract from either Salmonella minnesota R595 (Re LPS) or Escherichia coli J5 (Rc LPS), whereas the binding of Ab2 mAb PW-1 and PW-2 to 26-20 (Ab1) was only marginally inhibited by both Re LPS and Rc LPS. The results indicated that Ab2 mAb KM-04 recognizes a lipid A-binding site related idiotope on mAb 8-2 and therefore KM-04 might bear the internal image of a neutralization determining epitope of lipid A. Consequently Ab2 KM-04 might induce antibodies to lipid A. Indeed anti-idiotypic immunization of syngeneic BALB/c mice with Ab2 mAb KM-04 resulted in development of lipid A-binding anti-anti-idiotypic (Ab3) antibodies in serum. Similar immunizations with Ab2 mAb PW-1 and PW-2 were unsuccessful. However, induction of lipid A-binding Ab3 by mAb KM-04 proved to be genetically restricted to BALB/c mice. DBA/2 mice, Swiss mice and rabbits did not develop lipid A-binding antibodies upon immunization with mAb KM-04. In protection experiments, it was shown that BALB/c mice vaccinated with mAb KM-04 showed significantly enhanced survival from challenge with either rough (Re) LPS from Salmonella minnesota or smooth LPS from E. coli 0111:B4 when compared to BALB/c mice immunized with a non-relevant Ab2 mAb. The results suggest that mAb KM-04 constitutes a non-internal image vaccine to the lethal effect of lipid A in BALB/c mice. Furthermore an Ab3 mAb was prepared against Ab2 mAb KM-04 that showed reactivity with Re LPS. This Ab3 mAb, designated LE-21 (IgG2a) protected mice against an otherwise lethal challenge of Re LPS.

Full text

PDF
673

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altamirano-Bustamante A., Barnard G., Kohen F. Direct time-resolved fluorescence immunoassay for serum oestradiol based on the idiotypic anti-idiotypic approach. J Immunol Methods. 1991 Apr 8;138(1):95–101. doi: 10.1016/0022-1759(91)90068-q. [DOI] [PubMed] [Google Scholar]
  2. Boere W. A., Harmsen T., Vinjé J., Benaissa-Trouw B. J., Kraaijeveld C. A., Snippe H. Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities. J Virol. 1984 Nov;52(2):575–582. doi: 10.1128/jvi.52.2.575-582.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bruins S. C., Stumacher R., Johns M. A., McCabe W. R. Immunization with R mutants of Salmonella minnesota. II. Comparison of the protective effect of immunization with lipid A and the Re mutant. Infect Immun. 1977 Jul;17(1):16–20. doi: 10.1128/iai.17.1.16-20.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burdette S., Schwartz R. S. Current concepts: immunology. Idiotypes and idiotypic networks. N Engl J Med. 1987 Jul 23;317(4):219–224. doi: 10.1056/NEJM198707233170407. [DOI] [PubMed] [Google Scholar]
  5. Calandra T., Glauser M. P., Schellekens J., Verhoef J. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis. 1988 Aug;158(2):312–319. doi: 10.1093/infdis/158.2.312. [DOI] [PubMed] [Google Scholar]
  6. Cornelissen J. J., Mäkel I., Algra A., Benaissa-Trouw B. J., Schellekens J. F., Kraaijeveld C. A., Verhoef J. Protection against lethal endotoxemia by anti-lipid A murine monoclonal antibodies: comparison of efficacy with that of human anti-lipid A monoclonal antibody HA-1A. J Infect Dis. 1993 Apr;167(4):876–881. doi: 10.1093/infdis/167.4.876. [DOI] [PubMed] [Google Scholar]
  7. Cornelissen J. J., Oosterlaken T. A., Schellekens J., Torensma R., Rozenberg-Arska M., Kraaijeveld C. A., Verhoef J. Discrimination by rabbit anti-idiotypic antibodies of two murine IgM monoclonal antibodies directed against lipid A. J Immunol Methods. 1990 Jun 12;130(1):141–147. doi: 10.1016/0022-1759(90)90308-i. [DOI] [PubMed] [Google Scholar]
  8. Cornelissen J. J., Van Kessel C. P., Brouwer E., Kraaijeveld C. A., Verhoef J. Inhibition by lipid A-specific monoclonal antibodies of priming of human polymorphonuclear leucocytes by endotoxin. J Med Microbiol. 1991 Apr;34(4):233–238. doi: 10.1099/00222615-34-4-233. [DOI] [PubMed] [Google Scholar]
  9. Erich T., Schellekens J., Bouter A., Van Kranen J., Brouwer E., Verhoef J. Binding characteristics and cross-reactivity of three different antilipid A monoclonal antibodies. J Immunol. 1989 Dec 15;143(12):4053–4060. [PubMed] [Google Scholar]
  10. Hiernaux J. R. Idiotypic vaccines and infectious diseases. Infect Immun. 1988 Jun;56(6):1407–1413. doi: 10.1128/iai.56.6.1407-1413.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kato T., Takazoe I., Okuda K. Protection of mice against the lethal toxicity of a lipopolysaccharide (LPS) by immunization with anti-idiotype antibody to a monoclonal antibody to lipid A from Eikenella corrodens LPS. Infect Immun. 1990 Feb;58(2):416–420. doi: 10.1128/iai.58.2.416-420.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. McCabe W. R., DeMaria A., Jr, Berberich H., Johns M. A. Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J Infect Dis. 1988 Aug;158(2):291–300. doi: 10.1093/infdis/158.2.291. [DOI] [PubMed] [Google Scholar]
  14. Morrison D. C. Bacterial endotoxins and pathogenesis. Rev Infect Dis. 1983 Sep-Oct;5 (Suppl 4):S733–S747. doi: 10.1093/clinids/5.supplement_4.s733. [DOI] [PubMed] [Google Scholar]
  15. Nakane P. K., Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem. 1974 Dec;22(12):1084–1091. doi: 10.1177/22.12.1084. [DOI] [PubMed] [Google Scholar]
  16. Oosterlaken T. A., Harmsen M., Ekstijn G. L., Kraaijeveld C. A., Snippe H. IgVH determined genetic restriction of a non-internal image monoclonal anti-idiotypic vaccine against Semliki Forest virus. Immunology. 1992 Feb;75(2):224–231. [PMC free article] [PubMed] [Google Scholar]
  17. Pollack M., Huang A. I., Prescott R. K., Young L. S., Hunter K. W., Cruess D. F., Tsai C. M. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest. 1983 Dec;72(6):1874–1881. doi: 10.1172/JCI111150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rimmelzwaan G. F., Bunschoten E. J., UytdeHaag F. G., Osterhaus A. D. Monoclonal anti-idiotypic antibody vaccines against poliovirus, canine parvovirus, and rabies virus. Methods Enzymol. 1989;178:375–390. doi: 10.1016/0076-6879(89)78028-9. [DOI] [PubMed] [Google Scholar]
  19. Schick M. R., Dreesman G. R., Kennedy R. C. Induction of an anti-hepatitis B surface antigen response in mice by noninternal image (Ab2 alpha) anti-idiotypic antibodies. J Immunol. 1987 May 15;138(10):3419–3425. [PubMed] [Google Scholar]
  20. Su S. D., Ward M. M., Apicella M. A., Ward R. E. Analysis of the immune response to lipopolysaccharide. Existence of an interspecies cross-reactive idiotype associated with anti-lipid A antibodies. J Immunol. 1990 Nov 1;145(9):2994–3001. [PubMed] [Google Scholar]
  21. Su S., Ward M. M., Apicella M. A., Ward R. E. A nontoxic, idiotope vaccine against gram-negative bacterial infections. J Immunol. 1992 Jan 1;148(1):234–238. [PubMed] [Google Scholar]
  22. Torensma R., Fluit A. Mechanism for monoclonal antibody mediated treatment of gram-negative shock. Lancet. 1991 Jul 20;338(8760):186–186. doi: 10.1016/0140-6736(91)90174-n. [DOI] [PubMed] [Google Scholar]
  23. Weersink A. J., Van Kessel K. P., Torensma R., Van Strijp J. A., Verhoef J. Binding of rough lipopolysaccharides (LPS) to human leukocytes. Inhibition by anti-LPS monoclonal antibody. J Immunol. 1990 Jul 1;145(1):318–324. [PubMed] [Google Scholar]
  24. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  25. Ziegler E. J., McCutchan J. A., Fierer J., Glauser M. P., Sadoff J. C., Douglas H., Braude A. I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982 Nov 11;307(20):1225–1230. doi: 10.1056/NEJM198211113072001. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES